SciFi Futures
← Capabilities
Biotech & Medicine/Foundational science

Causal mechanisms of aging

Knowing which molecular changes actually cause age-related decline, and having a validated measure of biological age that responds to intervention.

State of the art

Partial reprogramming restored visual function in aged and injured mouse and macaque retina (2020-2024); FDA has qualified no epigenetic clock as a surrogate endpoint, so human aging trials still need disease endpoints.

What’s blocking it
  • No validated surrogate biomarker of biological age, so any whole-body rejuvenation claim needs decade-long outcome trials
  • Hallmarks of aging are correlated; interventions cannot yet be attributed to a specific causal node
  • Mouse lifespan results have repeatedly failed to transfer to longer-lived species

Who’s working on it

  • Partial epigenetic reprogramming (OSK); started the first human trial of ER-100 in optic neuropathies in Q1 2026 and raised an $80M Series D in April 2026

  • Dosed its first clinical candidate RTR242 in 2025 and raised a round at a $1.8B pre-money valuation in 2026, across cell therapy, reprogramming and protein design

  • Altos LabsStartup

    Launched in 2022 with roughly $3B to pursue cellular rejuvenation programming, the largest private bet on reprogramming-based aging biology

  • Steve HorvathResearcher
    Altos Labs

    Built the epigenetic clocks (2013 onward) that are the leading candidate biological-age measures; moved from UCLA to Altos Labs in 2022

  • Non-profit launched in 2021 in Riyadh that funds healthspan-biology grants and early-stage companies worldwide, the largest dedicated funder outside the NIH

  • NIA Interventions Testing ProgramProgram

    Runs blinded multi-site mouse lifespan trials that independently replicate candidate interventions, the field's main defence against non-reproducible results

What to invest in

KindInvestmentScale
researchInterventional nonhuman-primate cohorts with deep longitudinal multi-omic and functional phenotyping, long enough to test whether clocks track outcomes$$$ $100M – $1B
policyBiomarker qualification program so a measurable intermediate endpoint can support aging indications$$ $10M – $100M

Sci-fi concepts in reach

Human reproductive cloningdirectWhole-body rejuvenation treatmentgatingdirectRevival of the cryopreserved deaddirect

Sources